190 related articles for article (PubMed ID: 30671731)
1. Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Barth DA; Riedl JM; Posch F; Smolle MA; Kasparek AK; Niedrist T; Szkandera J; Stöger H; Pichler M; Stotz M; Gerger A
Clin Transl Oncol; 2019 Aug; 21(8):1034-1043. PubMed ID: 30671731
[TBL] [Abstract][Full Text] [Related]
2. Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study.
Chang J; Lin G; Ye M; Tong D; Zhao J; Zhu D; Yu Q; Zhang W; Li W
BMC Cancer; 2019 Jan; 19(1):15. PubMed ID: 30612568
[TBL] [Abstract][Full Text] [Related]
3. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy.
Tuncel T; Ozgun A; Emirzeoglu L; Celik S; Bilgi O; Karagoz B
Asian Pac J Cancer Prev; 2014; 15(15):6421-3. PubMed ID: 25124636
[TBL] [Abstract][Full Text] [Related]
4. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
[TBL] [Abstract][Full Text] [Related]
5. Elevated mean platelet volume predicts poor prognosis in colorectal cancer.
Li N; Yu Z; Zhang X; Liu T; Sun YX; Wang RT; Yu KJ
Sci Rep; 2017 Aug; 7(1):10261. PubMed ID: 28860547
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
[TBL] [Abstract][Full Text] [Related]
7. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients.
Zhang F; Chen Z; Wang P; Hu X; Gao Y; He J
Tumour Biol; 2016 Jul; 37(7):9323-31. PubMed ID: 26779631
[TBL] [Abstract][Full Text] [Related]
8. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
Lembeck AL; Posch F; Klocker EV; Szkandera J; Schlick K; Stojakovic T; Kornprat P; Lackner C; Gerger A; Stoeger H; Stotz M; Pichler M
Clin Chem Lab Med; 2019 Apr; 57(5):740-744. PubMed ID: 30307891
[TBL] [Abstract][Full Text] [Related]
9. Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer.
Sakin A; Sahin S; Sakin A; Karatas F; Sengul Samanci N; Yasar N; Arici S; Demir C; Geredeli C; Dikker O; Cihan S
J BUON; 2020; 25(1):227-239. PubMed ID: 32277636
[TBL] [Abstract][Full Text] [Related]
10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
11. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
13. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
14. The impact of chemotherapy-associated hemoglobin on prognosis of colorectal cancer patients receiving adjuvant chemotherapy.
Wei YS; Zhou YG; Wang GY; Liang ZH; Luo MR; Yang TA; Huang J
Cancer Biomark; 2017 Dec; 20(4):627-635. PubMed ID: 28800321
[TBL] [Abstract][Full Text] [Related]
15. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
16. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer.
Omar M; Tanriverdi O; Cokmert S; Oktay E; Yersal O; Pilancı KN; Menekse S; Kocar M; Sen CA; Ordu C; Goksel G; Meydan N; Barutca S;
Clin Respir J; 2018 Mar; 12(3):922-929. PubMed ID: 28026133
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
[TBL] [Abstract][Full Text] [Related]
19. Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
Watanabe K; Yasumoto A; Amano Y; Kage H; Goto Y; Yatomi Y; Takai D; Nagase T
PLoS One; 2018; 13(9):e0203625. PubMed ID: 30192878
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer.
Inagaki N; Kibata K; Tamaki T; Shimizu T; Nomura S
Lung Cancer; 2014 Jan; 83(1):97-101. PubMed ID: 24189108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
